title: Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF.
abstract: Three intraperitoneal human ovarian cancer xenografts (OS, HU, and LA) were used to assess the antitumour activity of intraperitoneal therapy with liposome encapsulated MTP-PE. MTP-PE led to significant prolongation of survival in all three xenograft models, but with varying efficacy. In one tumour model (OS), 80% of mice were cured of tumour by twice weekly therapy for 4 weeks, whereas in another xenograft model (LA), the median survival time was approximately doubled compared to PBS injected and placebo liposome injected controls (median survivals: 30 vs 62.5 days respectively). The antitumor efficacy of MTP-PE did not correlate with the extent of peritoneal neutrophil infiltration after intraperitoneal therapy. Combined therapy with liposome encapsulated MTP-PE and recombinant murine granulocyte-macrophage colony stimulating factor led to increased survival of mice bearing the LA and HU xenografts, compared to tumour bearing mice treated with either agent singly.
authors.affiliation: Biological Therapies Laboratory, Imperial Cancer Research Fund, Lincoln's Inn Fields, London.
authors.forename: S T
authors.initials: ST
authors.lastname: Malik
authors.forename: D
authors.initials: D
authors.lastname: Martin
authors.forename: I
authors.initials: I
authors.lastname: Hart
authors.forename: F
authors.initials: F
authors.lastname: Balkwill
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D008081:Liposomes / Q000008:administration & dosage; D051379:Mice; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010529:Peritoneal Cavity / Q000166:cytology; D010714:Phosphatidylethanolamines / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000008:administration & dosage; D014183:Transplantation, Heterologous
chemical_list: D000276:Adjuvants, Immunologic; D008081:Liposomes; D010714:Phosphatidylethanolamines; D011994:Recombinant Proteins; C037144:mifamurtide; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor